Request for Information (RFI): Commercial Off-the-Shelf Task Management Tool

The U.S. Food and Drug Administration Office of Acquisition and Grant Services is issuing a Request for Information (RFI) to assess market capability for Commercial Off-the-Shelf Task Management Tool (TMT) solutions to support enterprise-wide task management across the FDA. The RFI seeks vendors capable of providing comprehensive task management solutions with advanced features including configurable workflows, collaboration capabilities, robust reporting and analytics, granular user management, audit trails, AI-powered content generation, and integration with existing FDA systems. Key requirements include compliance with FedRAMP Moderate, FISMA, Section 508, and NIST standards, as well as compatibility with various cloud platforms and integration with the FDA's Elsa AI tool. Vendors are expected to provide an executive summary, capabilities overview, security and compliance information, integration and scalability details, use case alignment, preliminary cost estimates, and past performance references. The original response due date of November 15, 2025 was extended to November 20, 2025 at 5 PM EST through Amendment 1, with vendor questions due by October 31, 2025.

This procurement has no set-aside designation and includes no identified current contractors or incumbents. The anticipated user base includes approximately 20,000 FDA users, with potential future expansion to 80,000 users across the Department of Health and Human Services, with the user composition estimated at 90 percent view-only users, 10 percent power users, and approximately 50 administrators. While specific budget ranges have not been disclosed in the RFI documents, preliminary cost estimates for both FDA and HHS enterprise levels are being requested from vendors as part of their responses. The FDA's ExecSec office is expected to be the first to onboard, with the agency seeking to achieve immediate time and effort savings and potentially replace existing internal spreadsheets, Power Apps, and an Appian tool. The RFI indicates the FDA's preference for a FedRAMP SaaS solution with enterprise-wide pricing that requires minimal customization while offering configuration flexibility to address diverse operational needs across multiple FDA centers and functions.